Evidence map›Paper›PMID 34214163›Full record

Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Cytomegalovirus Viremia and Clinical Outcomes in Kenyan Children Diagnosed With Human Immunodeficiency Virus (HIV) in Hospital.

Dalton Wamalwa, Irene Njuguna, Elizabeth Maleche-Obimbo, Emily Begnel, Daisy J Chebet, Judith A Onyango, Lisa Marie Cranmer, Meei-Li Huang, Barbra A Richardson, Michael Boeckh and 2 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Dalton WamalwaDepartment of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Irene NjugunaKenyatta National Hospital, Nairobi, Kenya.
Elizabeth Maleche-ObimboDepartment of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Emily BegnelDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Daisy J ChebetDepartment of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Judith A OnyangoDepartment of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Lisa Marie CranmerDepartment of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Meei-Li HuangDepartments of Laboratory Medicine and Virology, Department of Global Health, University of Washington, Seattle, Washington, USA.
Barbra A RichardsonDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Michael BoeckhVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Grace John-StewartDepartment of Global Health, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-4301-1573
Jennifer SlykerDepartment of Global Health, University of Washington, Seattle, Washington, USA.
University of Washington · USUniversity of Nairobi · KEEmory University · US

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
INTERNATIONAL TRAINING GRANT IN EPIDEMIOLOGYD43TW000007 · FIC · UNIVERSITY OF WASHINGTON · PI FARQUHAR, CAREY · 1988 to 2012
$16.3M
Urgent Versus Post-Stabilization ART in HIV+ Children with Severe Co-infectionsR01HD023412 · NICHD · UNIVERSITY OF WASHINGTON · PI Grace C. John-Stewart, DALTON CHEKOKO WAMALWA · 1987 to 2026
$12.2M
Health-Professional Education Partnership Initiative (HEPI) - KenyaR25TW011212 · FIC · UNIVERSITY OF NAIROBI · PI NDUATI, RUTH WANJIRU, WAMALWA, DALTON CHEKOKO · 2018 to 2022
$3.2M
The role of antibodies in infant TB preventionK23AI143479 · NIAID · EMORY UNIVERSITY · PI CRANMER, LISA M · 2019 to 2023
$950k
CMV viremia and mortality in hospitalized HIV-infected childrenR21HD089821 · NICHD · UNIVERSITY OF WASHINGTON · PI SLYKER, JENNIFER ANN · 2018 to 2019
$444k
Epstein-Barr virus replication, malaria and clinical outcomes in hospitalized HIV infected childrenR21HD102825 · NICHD · UNIVERSITY OF WASHINGTON · PI SLYKER, JENNIFER ANN · 2020 to 2021
$428k
FIC NIH HHS D43 TW000007FIC NIH HHS R25 TW011212NIAID NIH HHS K23 AI143479NIAID NIH HHS P30 AI027757NICHD NIH HHS R01 HD023412NICHD NIH HHS R21 HD089821NICHD NIH HHS R21 HD102825
6 · The paper itself

Abstract

backgroundCytomegalovirus (CMV) viremia is common in human immunodeficiency virus (HIV) infection and is associated with worse long-term outcomes. To date, no studies have assessed CMV viremia in children diagnosed with HIV in hospital.

methodsWe studied CMV viremia and clinical outcomes in 163 Kenyan children aged 2 months to 12 years, diagnosed with HIV in hospital. CMV DNA levels in plasma were measured using quantitative polymerase chain reaction (PCR). Regression models were used to assess associations between CMV viremia ≥1000 IU/mL and the risk of continued hospitalization or death at 15 days, duration of hospitalization, and 6-month mortality.

resultsAt enrollment, 62/114 (54%) children had CMV viremia, and 20 (32%) were ≥1000 IU/mL. Eleven CMV reactivations were observed after admission. The prevalence and level of CMV viremia were highest in children <2 years and lowest in children ≥5 years old. CMV viremia ≥1000 IU/mL was independently associated with age <2 years (P = .03), higher log10 HIV RNA level (P = .01), and height-for-age z score >-2 (P = .02). Adjusting for age and log10 HIV RNA, the relative risk of death or continued hospitalization at 15 days was 1.74 (95% confidence interval [CI] = 1.04, 2.90), and the hazard ratio of 6-month mortality was 1.97 (95% CI = .57, 5.07) for children with CMV DNA ≥1000 IU/mL compared to lower-level or undetectable CMV DNA. Children with CMV DNA ≥1000 IU/mL were hospitalized a median ~5 days longer than children with lower-level or undetectable CMV DNA (P = .002).

conclusionsIn this nested observational study, CMV viremia was common in hospitalized children with HIV, and levels ≥1000 IU/mL were associated with increased risk of mortality and longer hospitalization.

Indexed as

Cytomegalovirus InfectionsHIV InfectionsChildChild, PreschoolCytomegalovirusHIVHospitalsHumansKenyaRNAViremiaRNAcritical carecytomegalovirushospitalhuman immunodeficiency virusviremia

Identifiers

PMID34214163
PMCPMC8994579
OpenAlexW3176990763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.